下尿路症状合并勃起功能障碍联合用药的有效性和安全性

目的:评价多沙唑嗪、非那雄胺和西地那非联合治疗BPH相关的LUTS和ED的有效性和安全性。方法:采用双盲、随机、安慰剂对照的临床研究,84例患者随机分入A、B、C组,A组服用多沙唑嗪、非那雄胺和安慰剂,B组服用多沙唑嗪、安慰剂和西地那非,C组服用多沙唑嗪、非那雄胺和西地那非。16周后比较各组的IIEF-5、IPSS、Qmax、夜尿次数和残余尿等,并记录不良反应。结果:A、B、C组的IIEF-5分别提高10.2%、57.1%和57.6%,IPSS分别降低22.2%、20.8%和20.1%。18例(21.4%)患者有较轻的不良反应。结论:多沙唑嗪、非那雄胺和西地那非联合治疗BPH相关的LUTS和ED是安全有效的。     

持续小剂量西地那非治疗早泄合并下尿路症状

目的 研究持续小剂量西地那非治疗早泄(PE)对良性前列腺增生症(BPH)引起的下尿路症状(LUTS)的影响.方法 82例PE同时伴有BPH的研究对象,随机分为2组,分别服用为期3个月的小剂量西地那非(A组)和左洛复(B组).在治疗前后行中国早泄指数评估表(CIPE)、国际前列腺症状评分表(IPSS)评分,比较其治疗前、后CIPE和IPSS评分.结果 治疗后A组CIPE明显增高,IPSS评分明显下降(P<0.01);B组CIPE明显增高(P<0.01),但IPSS评分轻度下降(P>0.05).结论 治疗中老年性PE合并BPH,小剂量西地那非既能有效治疗PE,又能改善由BPH引起的LUTS症状.     

前列腺电切对前列腺增生症患者下尿路症状和性功能的影响

目的 评估前列腺电切治疗前列腺增生症(BPH)患者下尿路症状(LUTS)和勃起功能障碍(ED)的疗效.方法 选择96例BPH合并ED患者,予以前列腺电切治疗.采用国际前列腺症状评分(IPSS)、国际勃起功能障碍症状评分(IIEF-5)来评估治疗前后的疗效.结果 患者治疗前后的IPPS评分比较,差异有统计学意义(P＜0.05),患者治疗前后的IIEF-5评分比较,差异无统计学意义(P＞0.05).结论 前列腺电切可有效治疗前列腺增生症的LUTS,但对ED无明显改善.     

α受体阻滞剂和非那雄胺对下尿路症状并勃起功能障碍的疗效对比研究

目的：比较a受体阻滞剂（坦索罗辛）和非那雄胺对下尿路症状（LUTS）并勃起功能障碍（ED）患者的疗效。方法：严格按照人组条件选择LUTS并ED患者80例,分别应用坦索罗辛和非那雄胺进行治疗,并比较两组国际勃起功能指数评分（IIEF-5）、国际前列腺症状评分（IPSS）、生活质量指数评分（QOL）的变化。结果：与治疗前相比,坦索罗辛组IIEF-5、IPSS、QOL三项检测指标均有明显改善,非那雄胺组IPSS和QOI．明显好转。结论：与非那雄胺相比,坦索罗辛对LUTS并ED具有明确疗效。     

M受体阻滞剂与α受体阻滞剂联合治疗良性前列腺增生的有效性及安全性研究

目的 评价M受体阻滞剂托特罗定与α受体阻滞剂多沙唑嗪联合治疗良性前列腺增生(BPH)患者的有效性及安全性.方法 2009年5月至2010年4月,选择刺激症状明显的BPH患者76例,主要的排除标准为最大尿流率(Qmax)＜10 ml/s、残余尿＞100 ml、前列腺体积＞50 ml.将患者随机分成2组:多沙唑嗪组(给予多沙唑嗪治疗,36例),联合用药组(给予托特罗定与多沙唑嗪联合治疗,40例).用药时间8周,评估内容包括国际前列腺症状评分(IPSS)、尿流率和残余尿量等,并登记不良事件.结果 两组间基线资料比较差异无统计学意义.用药8周后联合用药组IPSS评分由18.7±2.2降低到12.7±3.9(P=0.000),刺激症状评分由14.2±2.3降至9.1±3.1(P=0.000).多沙唑嗪组IPSS评分由18.6±3.0降低到15.2±3.8(P=0.033),刺激症状评分由12.7±3.0降至11.8±2.7(P=0.001).治疗后两组间比较显示:联合用药组IPSS评分的改善优于多沙唑嗪组(P＜0.01),联合用药组刺激评分的改善优于多沙唑嗪组(P＜0.01),而梗阻症状评分的改善两组间差异无统计学意义(P=0.168).治疗8周后两组间Qmax、残余尿差异无统计学意义(P＞0.05).联合用药组无急性尿潴留和其他严重并发症发生.结论 托特罗定与多沙唑嗪联合应用降低BPH患者IPSS评分,使其刺激症状获得明显的改善;未见严重不良反应和急性尿潴留出现.     

西地那非联合坦索罗辛治疗LUTS/BPH的对比研究

目的 观察西地那非联合坦索罗辛及单独应用坦索罗辛治疗良性前列腺增生症(BPH)所致下尿路症状(LUTS)的临床疗效.方法 国际前列腺症状评分(IPSS)≥12分的本院2010年7月～2011年6月BPH患者50例,随机分为两组,每组25例.治疗组口服西地那非25mg,每日一次+坦索罗辛0.2mg,每日两次;对照组服用坦索罗辛0.2mg,每日两次,疗程8周.治疗后组间比较IPSS、最大尿流率(Qmax)、残余尿量(PVR)、生活质量(QOL)和勃起功能国际问卷(IIEF-5),并进行统计学分析.结果 与对照组比较,治疗组IPSS明显下降,IIEF-5明显改善,QOL明显改善(P＜0.05),两组Qmax和PVR无明显差异(P＞0.05).结论 西地那非联合坦索罗辛治疗前列腺增生症所致下尿路症状优于单独应用坦索罗辛,并可以改善患者的勃起功能.     

良性前列腺增生症与勃起功能障碍的相关性研究

目的 研究中老年男性的下尿路症状(LUTS)与良性前列腺增生(BPH)及勃起功能障碍(ED)的相关性.方法 收集2006年1月至2008年2月在我院治疗的良性前列腺增生患者86例.对所有病例进行病史采集并进行统计学分析.结果 86例患者的ED患病率为68.60%.三个年龄组中ED的患病牢随着年龄的增加而升高.ED患病率随着LUTS程度的加重而逐渐升高.IPSS评分和残余尿量相关性良好(r=0.818,P<0.001);年龄和IIEF-5评分之间相关性良好(r=-0.688,P<0.001);IPSS评分和IIEF-5评分之间相关性良好(r=-0.686,P<0.001).控制年龄后进行统计分析,发现IPSS评分和IIEF-5评分之间仍然有相关性(r=-0.428,P<0.001).结论 前列腺体积和IPSS评分之间有弱相关性.残余尿量和IPSS评分之间相关性良好,说明残余尿量可以作为评价LUTS严重程度的一个重要指标.年龄、IPSS评分和IIEF-5评分的相关性良好,说明年龄和LUTS是ED的影响因素,其中LUTS是BPH引起ED的独立危险因素.     

男性下尿路症状和勃起功能障碍的相关性分析

目的:了解社区年龄≥50岁男性人群中有下尿路症状(LUTS)者ED的患病情况,评估LUTS(梗阻症状、刺激症状)和ED之间的相关性。方法:2006年10～11月对社区年龄≥50岁、有固定性伴侣的男性进行IPSS、IIEF-5调查,调查对象均签署知情同意书,完成规定问诊及相关检查,应用统计学方法对IPSS评分、梗阻症状评分以及刺激症状评分与勃起功能之间的相关性进行分析。结果:共调查245例,171例有LUTS患者中ED患病率为81.9%(140/171),无LUTS患者74例作为对照组,ED患病率为29.7%(22/74)。LUTS组中各年龄组ED的患病率分别为:50～59岁73.1%(38/52)、60～69岁82.1%(46/56)、≥70岁88.9%(56/63),各年龄组之间IPSS、IIEF-5比较差异有显著性(P<0.01),各年龄组之间轻、中、重度ED所占比例比较差异有显著性(P<0.01)。LUTS组中IPSS评分程度分布:轻度80例(46.8%)、中度67例(39.2%)、重度24例(14.0%),不同程度LUTS中ED者所占比例分别为:轻度LUTS71.3%(57/80)、中度LUTS89.6%(60/67)、重度LUTS95.8%(23/24),LUTS程度和ED患病率之间有显著相差性(r=0.52,P<0.01)。171例平均梗阻症状评分(3.1±3.6)分,梗阻症状与IIEF-5评分相关系数r=-0.41(P<0.01),平均刺激症状评分(6.8±4.9)分,刺激症状与IIEF-5评分相关系数r=-0.59(P<0.01)。结论:社区LUTS人群中ED有较高的患病率,LUTS程度和ED患病率显著性正相关,与梗阻症状相比刺激症状对中老年男性性生活的影响更大。在治疗LUTS的同时应该考虑ED问题,以求更有效改善患者生活质量。     

速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的研究

目的:探讨速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的疗效及安全性。方法:将64例BPH/LUTS夜尿增多患者随机均分为两组,一组患者给予多沙唑嗪(4 mg/d),另一组患者给予速尿(睡前6 h40 mg)联合多沙唑嗪,两组患者分别治疗4周后,记录并分析治疗前后患者的尿量、IPSS评分、QOL评分、血电解质和血浆渗透压变化情况。结果:速尿联合多沙唑嗪组与单用多沙唑嗪组比较,夜尿次数明显减少(P<0.01),白天尿量增加(P<0.01),夜间尿量减少(P<0.01),总尿量无明显改变(P>0.05),IPSS评分下降(P<0.05),QOL评分明显下降(P<0.01),血钠、钾、氯、渗透压无明显变化(P>0.05)。结论:速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的疗效明显,4周的治疗是安全的。     

良性前列腺增生症状参数与性功能关系的临床分析

目的 分析不同程度性功能情况下良性前列腺增生(BPH)症状参数的分布情况,并探讨两者间的相关性.方法 根据国际勃起功能问卷评分表(IIEF-5)和不同的射精功能情况,将BPH患者分为勃起功能正常、轻度、中度和重度障碍4组和射精正常、射精量减少、射精痛或射精不适和早泄4组,分析各组间的下尿路症状(LUTS)、前列腺总体积(TPV)、最大尿流率(Qmax)间的情况,应用方差分析研究各参数间的差异,并探讨两者间的关系.结果 BPH患者165例,年龄53～75岁.144例有勃起功能障碍(ED)(87.27%),140例有射精功能障碍(EjD)(84.85%).研究显示:年龄与性功能关系密切.TPV在IIEF-5评分正常组与重度ED组间比较,差异有统计学意义;IPSS评分在IIEF-5正常组与轻、中、重度ED组间比较,差异有统计学意义.IPSS评分在射精正常组与精液量减少、射精痛或射精不适的组间比较,差异有统计学意义.结论 年龄是性功能障碍的主要因素.BPH患者中ED和EjD的发生率较高.ED的程度与LUTS的严重程度和TPV大小之间有相关性,而不同的射精障碍与LUTS的严重程度也有相关性.     

An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia

This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS). The trial was conducted in hospitals in Beijing, Shanghai, Changsha, Wuhan and Guangzhou, five major cities in China. A total of 250 patients diagnosed with ED and BPH/LUTS aged 50-75 years, and who had International Index of Erection Function-5 (IIEF-5) scores ≤21 and International Prostate Symptom Score (IPSS) ≥10 points, were enrolled and randomly divided into Group A (168 cases; doxazosin GITS 4 mg once daily plus sildenafil 25-100 mg on demand) and Group B (82 cases; sildenafil 25-100 mg on demand). Efficacies were evaluated by IIEF-5 and IPSS scores and a quality of life (QoL) questionnaire, and adverse effects were evaluated during the treatment period. There were no statistically significant differences in mean age, and IIEF-5, IPSS and QoL scores pre-treatment between the two groups. After treatment, IIEF-5, IPSS and QoL scores were significantly improved in Group A, while only IIEF-5 scores were significantly improved in Group B compared with pre-treatment. There were no significant differences in side effects between the two groups. The results indicated that combined therapy with sildenafil and doxazosin GITS for the treatment of ED and BPH/LUTS is safe and effective compared to sildenafil monotherapy.     

The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis

We evaluated the effectiveness of sildenafil citrate on lower urinary system symptoms (LUTS) by using symptom score scales. We also evaluated whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the alteration in the symptom scores. A total of 36 male patients were included in the study. For all the cases, 'International Prostate Symptom Score' (IPSS), 'National Health Institute Chronic Prostatitis Symptom Index' (NIH-CPSI) and 'International Index of Erectile Function' (IIEF-5) were investigated and the scores were calculated in the first visit. Sildenafil citrate was given for 30 days and at the second visit IPSS, NIH-CPSI and IIEF-5 scores were once more analyzed. Afterwards, the alterations of the scores between visits were statistically compared. Mean age of the 36 cases included in the study was 59.03±1.35. When the alterations in parameters of first visit and second visit were evaluated, we found a statistically significant increase in IIEF-5 and a statistically significant decrease in IPSS, IPSS-QOL (Quality of Life). In addition, when the cases were divided into two groups with and without asymptomatic inflammatory prostatitis, in the cases with asymptomatic inflammatory prostatitis, sildenafil citrate caused improvement only in ED, but had no effect on LUTS. Sildenafil citrate use in cases with LUTS and ED has an improving effect on LUTS as well as ED. However, in cases with asymptomatic inflammatory prostatitis, sildenafil citrate did not lead to an improvement in LUTS.     

万艾可治疗ED时对BPH引起LUTS改善的研究

目的 :探索、研究万艾可在治疗阴茎勃起功能障碍 (ED)时对由良性前列腺增生 (BPH)引起的下尿路症状(LUTS)的影响。　方法 :32例ED同时伴有BPH的研究对象 ,采用IIEF 5问卷表和IPSS评分表 ,在服用万艾可前和服药后 6个月分别各填写一次 ,应用单因素方差分析对所得到的前后评分进行统计学分析。结果 :在服药前32例ED中 ,轻、中、重分别为 14、13、5例 ,BPH中轻、中、重分别为 3、15、14例 ;服药后IIEF 5评分平均上升4 2 .36 % ,IPSS评分平均下降 2 0 .14 % ,两者在统计学上都有显著性差异 ,P <0 .0 1。　结论 :在治疗中老年性ED合并BPH中 ,应用万艾可既能治疗ED ,取得完美的性生活 ,又能达到改善由BPH引起的LUTS。万艾可是一治疗ED有效的药物 ,但对于前列腺基质平滑肌亦有辅助性松弛作用 ,因此也有助于BPH时LUTS的缓解。     

Association between ED and LUTS in Japanese motorcyclists

Recently, the association between motorcycling and erectile dysfunction (ED) has been reported. Also, lower urinary tract symptoms (LUTS) were reported to be associated with ED. The aim of this study is to evaluate the association of ED with LUTS in motorcyclists. We investigated the prevalence and the status of ED using a 5-item version of the International Index of Erectile Function (IIEF-5) in 150 motorcyclists. ED was diagnosed when the IIEF-5 score was less than 17. The International Prostate Symptom Score (IPSS) was also applied, and the relationship between IIEF-5 and IPSS was evaluated. Of the 150 motorcyclists, 37 (25%) had ED, and 31 (21%) had moderate or severe symptoms of LUTS (IPSS >or=8). The IIEF-5 was significantly associated with the severity of IPSS (P=0.002) and age (P<0.0001). The IIEF-5 was also significantly associated with the scores of both voiding (P<0.0001) and storage symptoms (P=0.001). On stepwise logistic regression analysis, age and storage symptoms are independent risk factors for ED in motorcyclists. LUTS seemed to be associated with ED in motorcyclists.     

长期小剂量西地那非治疗难治性勃起功能障碍的初步研究(附37例报告)

目的探讨长期、小剂量两地那非治疗难治性勃起功能障碍(ED)的机制。方法回顾性分析2004年12月至2005年10月间我院门诊收治的37例难治性ED患者临床资料。结果37例患者都完成了6周小剂量两地那非治疗。服药2周后勃起功能改善明显。第6周完成治疗后疗效满意,34例(91．89％)患者IIEF- 5评分、勃起硬度达到正常;停药后第2周及第6周复诊,33例患者疗效维持,4例稍有下降。结论长期服用小剂量西地那非治疗难治性ED患者疗效良好,其机制仍待探讨、证实。     

Association between lower urinary tract symptoms and sexual dysfunction in Taiwanese men

The study investigated the association between lower urinary tract symptoms (LUTS) and sexual dysfunction in ageing men. It was a cross-sectional study in an unselected consecutive sample of 398 men aged >40 years attending a urology clinic. LUTS and sexual function were assessed by validated symptom scales, including the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function-5 (IIEF-5). Clinically the severity of total and obstructive IPSS showed no significant correlation with age, but irritative IPSS is statistically correlated with age (P < 0.05). The prevalence of moderate to severe ED (IIEF-5 < 12) was significantly associated with LUTS severity (P < 0.05) and the severity of IIEF-5 correlated significantly with age (P < 0.01). A consistent inverse correlation was found between IIEF-5 and IPSS severity across the age groups, with the strongest effect within aged 60 to 69 years (r = −0.286, P < 0.01). The irritative IPSS showed a significant correlation with IIEF-5 severity across all age groups. These results reveal a significant correlation between LUTS and the severity of ED, especially on the irritative domain.     

Relationships between lower urinary tract symptoms, the bother they induce and erectile dysfunction

OBJECTIVE: To study the relationships between lower urinary tract symptoms (LUTS), LUTS-induced bother, age and erectile dysfunction. MATERIAL AND METHODS: A survey consisting of two questionnaires, the International Prostate Symptom Score (IPSS) (reflecting LUTS) and the International Index of Erectile Function (IIEF)-5 (reflecting erectile function), together with instructions on how to perform timed micturition, was sent to 2000 randomly selected men (age range 60-70 years) living in the five counties surrounding our hospital. The IPSS questionnaire included a question concerning the degree of bother induced by LUTS. RESULTS: The survey was answered by 1096 men; after the exclusion of incomplete answers, 924 surveys were evaluated. Of these 924 men, 725 (78%) were sexually active and included in the analyses. The prevalence of moderate-to-severe LUTS (IPSS>or=8) was 45%. The prevalence of erectile dysfunction (ED), defined as an IIEF-5 score of 相似文献   

Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time

Sildenafil is one of two oral drugs approved for first-line treatment of erectile dysfunction (ED). Anecdotally, some young healthy men who wish to enhance their sexual performance are requesting or abusing sildenafil. In this randomized double-blind, placebo-controlled clinical study, we investigated the effect of sildenafil in young men without ED. A total of 60 young healthy men age 20-40 y with no reported ED were enrolled for this single-dose home-use study. Subjects had used no medication in the 6 months prior to the study. All had been engaged in a stable relationship for at least 3 months. After completing the IIEF-5 questionnaire, patients were randomized in a double-blind fashion to receive either one 25 mg tablet of sildenafil (group 1) taken prior to intercourse, or an identical placebo tablet (group 2). All subjects completed a questionnaire relating to their erectile quality. There were no differences between the two groups in the reported improvement of erection quality, 12/30 sildenafil vs 10/30 placebo (Fisher's test, P=0.79). Sildenafil caused a significant reduction of the postejaculatory refractory time (12/30 vs 4/30) (chi(2) test, P=0.04). Sildenafil does not improve erections in young healthy men. Sildenafil should not be given to young healthy men to improve their erections and patients should be advised against recreational abuse of the drug. In this limited single-dose home study, sildenafil appears to reduce the postorgasmic refractory time. Although controlled studies are needed to evaluate the efficacy of erection-enhancing drugs in premature ejaculation, it is possible that sildenafil might be useful for this indication.